全球肝病负担与研究趋势:基于中国视角的分析
本文从中国视角综述全球肝病负担与研究趋势。发达国家病毒性肝炎发病率因预防、诊断和治疗进步及乙肝免疫规划扩展而下降,而代谢性肝病(非酒精性脂肪性肝病和酒精相关肝病)患病率随生活水平提高而上升,最终导致更多终末期肝病。文章比较了中国与美国、欧洲国家和日本在肝病流行病学、机构研究概况、资助格局和药物开发趋势方面的状况与成就。
要点
- 发达国家病毒性肝炎发病率因预防、诊断和治疗进步及乙肝免疫规划扩展而下降。
- 代谢性肝病包括非酒精性脂肪性肝病和酒精相关肝病患病率随生活水平提高而上升,导致更多终末期肝病。
- 中国通过全国预防措施、全球伙伴关系和青年肝病学家辅导计划努力摆脱「肝病领导者」称号,国家自然科学基金持续支持肝病研究。
核心结论
- 全球肝病负担正在变化:病毒性肝炎发病率在发达国家下降,而代谢性肝病患病率上升,导致终末期肝病增加。
- 中国在肝病研究、预防和药物开发方面取得进展,并努力通过全国措施和全球合作改善肝病状况。
研究设计与样本
- 本文为综述,分析全球肝病负担和研究趋势,比较中国与美国、欧洲国家和日本在肝病流行病学、机构研究概况、资助格局和药物开发趋势方面的状况。
主要发现
- 在多数发达国家,病毒性肝炎发病率因预防、诊断和治疗进步而下降。
- 包括中国在内的许多国家,乙肝病毒系统免疫规划扩展显著减少了新发病例。
- 随着生活水平提高,包括非酒精性脂肪性肝病和酒精相关肝病在内的代谢性肝病患病率将上升,最终导致更多终末期肝病(肝衰竭、肝硬化和肝癌)病例。
- 过去30年,主要国家政府为肝病领域的基础/临床研究、疫苗接种规划及药物发现和开发提供了强力激励。
- 中国通过全国预防措施、全球伙伴关系和青年肝病学家辅导计划努力摆脱「肝病领导者」称号,国家自然科学基金持续支持使肝病研究在国内几乎所有研究方向蓬勃发展。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Liver diseases affect millions of people worldwide. In most developed countries, the incidence of viral hepatitis is waning as a result of modern advances in disease prevention, diagnosis, and therapies. Expanded programmes for systematic immunisation against hepatitis B virus have also significantly brought down the number of new cases in many countries, including China. In contrast, with the improvement in living standards, the prevalence of metabolic liver diseases including non-alcoholic fatty liver disease and alcohol-related liver disease is set to rise, ultimately leading to more cases of end-stage liver diseases (liver failure, cirrhosis, and liver cancer). Over the past 30 years, visionary governments of major nations have provided strong incentives for basic/clinical research, vaccination programmes, and drug discovery and development in the field of hepatology. To get rid of her unflattering title as the "leader in liver diseases", China has also made a serious effort to initiate nationwide preventive measures for liver diseases, global partnerships, and mentoring programmes for young hepatologists. Instrumental to such progress is the continuous support of the National Natural Science Foundation of China (NSFC), which has helped hepatology to thrive in virtually all research directions within the country. In this article, we seek to provide stimulating glimpses into the evolving liver disease epidemiology, institutional research profiles, funding landscape, and drug development trends in China, with an attempt to compare her status and achievements with those of the United States, European countries, and Japan.
引用
- Xiao J, Wang F, Wong NK, et al. Global liver disease burdens and research trends: Analysis from a Chinese perspective. J Hepatol. 2019. PMID: 30871980. doi:10.1016/j.jhep.2019.03.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。